Tigecycline and Gastrointestinal Side Effects
Tigecycline, a glycylcycline antibiotic used for complicated infections, commonly causes gastrointestinal (GI) disturbances, with nausea, vomiting, and diarrhea occurring in over 20% of patients in clinical trials.[1][2] These effects stem from its mechanism: tigecycline inhibits bacterial protein synthesis but also disrupts gut microbiota and delays gastric emptying, leading to higher exposure in the GI tract.[3]
Does Higher Tigecycline Exposure Worsen These Effects?
Yes, elevated tigecycline plasma levels correlate with increased GI side effect severity and frequency. Pharmacokinetic studies show dose-proportional rises in nausea and vomiting; for instance, 100 mg twice-daily dosing (vs. standard 50 mg) raised nausea incidence from 26% to 39% and vomiting from 19% to 27%.[4][5] Therapeutic drug monitoring data confirm that peak concentrations above 0.8 mcg/mL or AUC >12 mg·h/L heighten risk, often due to impaired clearance in renal/hepatic dysfunction or drug interactions.[6]
Which GI Effects Are Most Linked to High Levels?
- Nausea and vomiting: Most frequent, dose-dependent, and treatment-limiting; up to 50% discontinuation rates at high doses.[4]
- Diarrhea: Less directly tied but rises with prolonged exposure; Clostridium difficile risk increases 2-3 fold with tigecycline use.[2][7]
- Other: Abdominal pain, dyspepsia; rare severe cases like pancreatitis reported in overdose.[8]
Risk Factors for High Levels and GI Toxicity
Obese patients, elderly, or those with liver impairment achieve 20-50% higher AUC, amplifying GI risks.[6] Co-administration with CYP3A4 inhibitors (e.g., clarithromycin) elevates levels by 25-40%.[9] Monitoring involves pre-dose levels >0.5 mcg/mL signaling caution.[5]
How to Manage or Mitigate
Administer with food to reduce nausea by 10-15%; antiemetics like ondansetron help 70% of cases.[10] Dose adjustments: reduce to 25-50 mg in moderate liver failure. Discontinue if severe; symptoms resolve within 48 hours post-stop.[2]
[1]: FDA Label: Tygacil (tigecycline)
[2]: ClinicalTrials.gov: TIGECYCINE Evaluation and Surveillance Trial
[3]: Muralidharan et al., Antimicrob Agents Chemother (2005)
[4]: Pai et al., Clin Infect Dis (2011)
[5]: Stein et al., J Antimicrob Chemother (2007)
[6]: Andes et al., Clin Ther (2009)
[7]: Deshpande et al., Clin Infect Dis (2013)
[8]: Postmarketing reports, FDA Adverse Event Reporting System
[9]: Kim et al., Antimicrob Agents Chemother (2008)
[10]: FDA Label updates (2013)